The FDA advisory committee recently approved the use of AMX0035 for the treatment of ALS. Presented with the robustness of new evidence, the committee reversed their March 2022 vote overwhelming by a 7-2 vote. The ALS Association has publicly thanked both the FDA advisory committee and the entire ALS community for their hard work and advocacy.
